Shandong University: Thrombocytopenia trials

The registry lists 40 Thrombocytopenia studies with Shandong University as lead sponsor. 3 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 13Phase 3 16Phase 4 5No phase 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• The Study of Different Cycles of High-dose Dexamethasone in the Treatment of ITPNot yet recruitingNCT06913374Phase 2/3
• A Multicenter Randomized Controlled Study on the Treatment of Refractory CTIT With Romiplostim N01 Compared to Recombinant Human ThrombopoietinNot yet recruitingNCT06440824Phase 3
• High-dose Dexamethasone Plus Hetrombopag vs High-dose Dexamethasone Alone as Frontline Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Prospective, Multicenter, Randomized TrialRecruitingNCT05943691Phase 2
• A Multicenter Randomized Open-label Study of Chidamide Plus HD-DEX Versus HD-DEX in ITPStatus unknownNCT05411874Phase 2
• A Clinical Trial of the Orelabrutinib in the Management of Refractory ITPStatus unknownNCT05020288Phase 2
• Avatrombopag in the Treatment of Primary Immune Thrombocytopenia(ITP)Status unknownNCT04949009
• Connection Between Vitamin D Level and the Efficacy of Dexamethasone in Immune ThrombocytopeniaStatus unknownNCT04320225
• A Multicenter Randomized Study of Vitamin D Combined With HD-DXM Versus HD-DXM for the Treatment of ITPStatus unknownNCT04094805Phase 4
• Glycyrrhetinic Acid Combined With Dexamethasone in Management of Newly Diagnosed ITPStatus unknownNCT03998982Phase 4
• A Clinical Trial of Chidamide in the Management of Refractory ITPCompletedNCT03838354Phase 1/2
• A Prospective, Open, Multicenter Clinical Trial of Eltrombopag Combined With Diacerein in Eltrombopag-inefficient or Relapsed ITPCompletedNCT03754634Phase 2
• Atorvastatin in Management of Newly Diagnosed ITPStatus unknownNCT03692754Phase 2/3
• Recombinant Human Thrombopoietin(rhTPO) in Pregnancy With Immune ThrombocytopeniaStatus unknownNCT03492515Phase 3
• Rituximab Combining Bortezomib Versus Rituximab in Management of ITPStatus unknownNCT03443570Phase 3
• The Association Between Platelet Reactivity and Bleeding Risk in Adult ITPStatus unknownNCT03377439
• Evaluation of HRQoL in Adult With Immune Thrombocytopenia in ChinaStatus unknownNCT03324087
• The Study of Different Dose Rituximab in the Treatment of ITPCompletedNCT03258866Phase 4
• Decitabine Combining Dexamethasone Versus Dexamethasone in Management of ITPStatus unknownNCT03252457Phase 3
• Clinical Trial of Gut Microbiota in the Management of Immune ThrombocytopeniaStatus unknownNCT03033199Phase 2
• A Single-center Clinical Trial of Bortezomib in Management of Immune Thrombocytopenia (ITP)Status unknownNCT03013114Phase 2
• RP% Measurement by FCM as a Diagnostic Test for ITPStatus unknownNCT02967328
• DEX Combined With RTX, CSA and IVIG in the Management of Newly Diagnosed ITP PatientsStatus unknownNCT02834468Phase 3
• Different Cycles of High-dose Dexamethasone for Initial Management of Primary Immune Thrombocytopenia (ITP)WithdrawnNCT02642380Phase 4
• Caffeic Acid Combining High-dose Dexamethasone in Management of ITPCompletedNCT02556814Phase 4
• A Multicenter Study on Recombinant Human Thrombopoietin in Management of ITP in PregnancyCompletedNCT02391272Phase 3
• Caffeic Acid Tablets as a Second-line Therapy for ITPCompletedNCT02351622Phase 3
• Recombinant Human Thrombopoietin (rhTPO) in Management of Immune Thrombocytopenia (ITP) in PregnancyStatus unknownNCT02270801Phase 3
• Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic LeukemiaStatus unknownNCT02244658Phase 3
• A Multicenter Investigation of Recombinant Human Thrombopoietin (rhTPO) Combining Cyclosporin A Versus Cyclosporin A in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia （ITP）WithdrawnNCT02203422Phase 3
• An Investigation of Dexamethasone With Different Doses in the Management of Immune Thrombocytopenia (ITP)CompletedNCT02153060Phase 2
• An Investigation of rhTPO With Different Frequencies in the Management of ITPCompletedNCT02139501Phase 3
• A Multicentre Investigation of 2 Cycles Rituximab Compared With Standard Regimen in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia （ITP）WithdrawnNCT02137681Phase 3
• High-dose Dexamethasone Combining Thalidomide Versus Dexamethasone Mono-therapy for Management of Newly-diagnosed ITPWithdrawnNCT01976195Phase 2
• A Multicenter Randomized Open-label Study of Oseltamivir Combined With HD-DEX Versus HD-DEX in the Management of ITPCompletedNCT01965626Phase 2
• All-Trans Retinoic Acid (ATRA) Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)WithdrawnNCT01882127Phase 3
• The Alteration of Macrophage Function in the Spleen Tissues From Patients With Primary Immune ThrombocytopeniaWithdrawnNCT01869049
• Alteration of Different Immune Parameters in Immune Thrombocytopenia （ITP） Patients Receiving Eltrombopag TreatmentWithdrawnNCT01864512
• Recombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)WithdrawnNCT01734057Phase 3
• Autoantibody Specificity and Response to IVIG in ITPCompletedNCT01666795
• A Multi-center Study of Low-dose Decitabine for the Treatment of Immune ThrombocytopeniaCompletedNCT01568333Phase 2